Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Biochemical and Biophysical Research Communications - BBRC

• Publication date

  2001-02-09

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1006/BBRC.2001.4267PMID 11162657
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Amplification of 4q21–q22 and the MXR gene in independently derived mitoxantrone‐resistant cell lines

  2000cited by this paper
• Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein.

  2000cited by this paper
• Novel mechanisms of drug resistance in leukemia

  2000cited by this paper
• Biochemical, cellular, and pharmacological aspects of the multidrug transporter.

  1999cited by this paper
• Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance.

  1999cited by this paper
• Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus.

  1999cited by this paper
• Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells.

  1999cited by this paper
• Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line.

  1999cited by this paper
• Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes.

  1999cited by this paper
• High-performance liquid chromatographic method for the simultaneous determination of the camptothecin derivative irinotecan hydrochloride, CPT-11, and its metabolites SN-38 and SN-38 glucuronide in rat plasma with a fully automated on-line solid-phase extraction system, PROSPEKT.

  1999cited by this paper
• The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin.

  1999cited by this paper
• The multidrug resistance protein family.

  1999cited by this paper
• Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.

  1999cited by this paper
• ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P.

  1999cited by this paper
• An inventory of the human ABC proteins.

  1999cited by this paper
• Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines.

  1999cited by this paper
• Phase I study of irinotecan combined with carboplatin in previously untreated solid cancers.

  1999cited by this paper
• A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance.

  1998cited by this paper
• Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C.

  1998cited by this paper
• A multidrug resistance transporter from human MCF-7 breast cancer cells.

  1998cited by this paper
• Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters.

  1998cited by this paper
• Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.

  1998cited by this paper
• Expression of the UDP-glucuronosyltransferase 1A Locus in Human Colon

  1998cited by this paper
• Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.

  1998cited by this paper
• A novel quinoline derivative, MS-209, overcomes drug resistance of human lung cancer cells expressing the multidrug resistance-associated protein (MRP) gene

  1997cited by this paper
• DX‐8951F, a water‐soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN‐38‐resistant variant

  1997cited by this paper
• The Role of Glucuronidation in 7‐Ethyl‐10‐hydroxycamptothecin Resistance in vitro

  1997cited by this paper
• Human canalicular multispecific organic anion transporter (cMOAT) is expressed in human lung, gastric, and colorectal cancer cells.

  1997cited by this paper
• Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations.

  1995cited by this paper
• Expression of wild-type p53 during the cell cycle in normal human mammary epithelial cells.

  1994cited by this paper
• Reduced intracellular drug accumulation in the absence of P-glycoprotein (mdr1) overexpression in mitoxantrone-resistant human MCF-7 breast cancer cells.

  1992cited by this paper
• Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion.

  1991cited by this paper
• Cloning of two human liver bilirubin UDP-glucuronosyltransferase cDNAs with expression in COS-1 cells.

  1991cited by this paper
• Membrane vesicle formation due to acquired mitoxantrone resistance in human gastric carcinoma cell line EPG85-257.

  1990cited by this paper
• Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.

  1985cited by this paper

• Evaluation of the effect of ethylmethylhydroxypyridine succinate on the activity of the BCRP transporter protein in vitro

  2025cites this paper
• rs2231142 (421 C>A, Q141K) Is More Functionally Influential than rs2231137 (34 G>A, V12M) on Anticancer Drug Resistance Mediated by the ABCG2 Haplotype In Vitro

  2025cites this paper
• The Kinase Inhibitor GNF-7 Is Synthetically Lethal in Topoisomerase 1-Deficient Ewing Sarcoma

  2025cites this paper
• Expression and interaction of RNA binding protein HuR with multidrug transporters (P-GP, MRP1, and ABCG2) in chemoresistant breast and colorectal cancer cells

  2025cites this paper
• Understanding Cancer’s Defense against Topoisomerase-Active Drugs: A Comprehensive Review

  2024cites this paper
• A comprehensive update of hormone-related pharmacokinetic variations associated with breast cancer drugs

  2023cites this paper
• Toward a Better Understanding of NRF2/NFE2L2 and BCRP/ABCG2 in Therapy Resistance in Cancer

  2023cites this paper
• Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patients

  2022cites this paper
• The role of polyphenols in overcoming cancer drug resistance: a comprehensive review

  2022cites this paper
• Functional Alterations of Multidrug Resistance-Associated Proteins 2 and 5, and Breast Cancer Resistance Protein upon Snail-Induced Epithelial-Mesenchymal Transition in HCC827 Cells.

  2021cites this paper
• Extracellular Vesicles in Chemoresistance.

  2021cites this paper
• Breast Cancer Resistance Protein: A Potential Therapeutic Target for Cancer.

  2020cites this paper
• Superior Pyrimidine Derivatives as Selective ABCG2 Inhibitors and Broad-spectrum ABCB1, ABCC1, and ABCG2 Antagonists.

  2020cites this paper
• Predictive biomarkers of drug resistance in colorectal cancer—Recent updates

  2020cites this paper
• TRPS1 Confers Multidrug Resistance of Breast Cancer Cells by Regulating BCRP Expression

  2020cites this paper
• Development of precision medicine approaches based on inter-individual variability of BCRP/ABCG2

  2019cites this paper
• Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy

  2019cites this paper
• Development of a Split Esterase for Protein–Protein Interaction-Dependent Small-Molecule Activation

  2019cites this paper
• Identification and Characterization of Efflux Transporters That Modulate the Subtoxic Disposition of Diclofenac and Its Metabolites

  2019cites this paper
• Recent advances in the search of BCRP- and dual P-gp/BCRP-based multidrug resistance modulators

  2019cites this paper
• Gene-by-Environment Interaction of Bcrp−/− and Methionine- and Choline-Deficient Diet–Induced Nonalcoholic Steatohepatitis Alters SN-38 Disposition

  2018cites this paper
• Change in Topoisomerase 1–Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol

  2018cites this paper
• Human non-small cell lung cancer cells can be sensitized to camptothecin by modulating autophagy

  2018cites this paper
• Characterization of Camptothecin-induced Genomic Changes in the Camptothecin-resistant T-ALL-derived Cell Line CPT-K5.

  2018cites this paper
• The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target

  2018cites this paper
• Breast Cancer Resistance Protein and Multidrug Resistance Protein 2 Regulate the Disposition of Acacetin Glucuronides

  2017cites this paper
• Effect of Liver Disease on Hepatic Transporter Expression and Function.

  2017cites this paper
• Cancer chemoresistance; biochemical and molecular aspects: a brief overview.

  2016cites this paper
• Synthesis and Pharmacological Evaluation of Maleopimaric N-arylimides: Identification of Novel Proapoptotic Agents.

  2016cites this paper
• Combining ABCG2 Inhibitors with IMMU-132, an Anti–Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers

  2016cites this paper
• Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies.

  2016cites this paper
• [Role of breast cancer resistance protein in drug disposition].

  2016cites this paper
• Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines

  2016cites this paper
• ABCG2 expression in colorectal adenocarcinomas may predict resistance to irinotecan.

  2016influential citation
• Drugs Affecting Epigenetic Modifications of ABC Transporters for Drug Resistance

  2015cites this paper
• Preliminary study of the effects of β-elemene on MCF-7/ADM breast cancer stem cells.

  2015cites this paper
• Interplay of Breast Cancer Resistance Protein (BCRP) and Metabolizing Enzymes.

  2015cites this paper
• Pharmacokinetic strategies to improve drug penetration and entrapment within solid tumors.

  2015cites this paper
• Novel pharmacogenomic markers of irinotecan-induced severe toxicity in metastatic colorectal cancer patients

  2015cites this paper
• FL118, a novel camptothecin analogue, overcomes irinotecan and topotecan resistance in human tumor xenograft models.

  2015cites this paper
• Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.

  2015cites this paper
• The Modulation of Non-steroidal Anti-inflammatory Toxicity as a Function of the Interplay between Uptake and Efflux Transporters

  2015cites this paper
• Investigation of the pharmacokinetics of the ABCG2 transporter inhibitor Ko134 in mice by a newly developed and validated HPLC method

  2014cites this paper
• The Activated MEK/ERK Pathway may Potentiate Breast Cancer Resistance Protein /ABCG2 Function in SN38-selected MCF-

  2014cites this paper
• Identification et mécanisme d'action de modulateurs sélectifs du transporteur ABCG2 responsable de la chimiorésistance de cellules cancéreuses

  2014cites this paper
• The Activated MEK / ERK Pathway may Potentiate Breast Cancer Resistance Protein / ABCG 2 Function in SN 38-selected MCF-7 Cells

  2014cites this paper
• Construction of indoloquinolinones via Pd(II)-catalyzed tandem CC/CN bond formation: application to the total synthesis of isocryptolepine

  2014cites this paper
• Mechanisms of P-glycoprotein alteration during anticancer treatment: role in the pharmacokinetic and pharmacological effects of various substrate drugs.

  2014cites this paper
• 抗がん剤治療時における P-glycoproteinの発現・機能変動と薬物動態並びに薬理作用へ及ぼす影響

  2014cites this paper
• Drug Transport in the Liver

  2014cites this paper
• THE DEVELOPMENT AND VALIDATION OF A CHIRAL HIGH PERFORMANCE LIQUID CHROMATOGRAPHY METHOD FOR THE IDENTIFICATION AND QUANTIFICATION OF ( R )-ENANTIOMER IN 7-ETHYL-10-HYDROXYCAMPTOTHECIN ( SN-38 )

  2014cites this paper
• ABC Transporters: Involvement in Multidrug Resistance and Drug Disposition

  2014cites this paper
• P-glycoprotein inhibitors of natural origin as potential tumor chemo-sensitizers: A review

  2014cites this paper
• [Molecular fundamentals of drug interactions in the therapy of colorectal cancer].

  2014cites this paper
• An Experimental Approach To Evaluate the Impact of Impaired Transport Function on Hepatobiliary Drug Disposition Using Mrp2-Deficient TR– Rat Sandwich-Cultured Hepatocytes in Combination with Bcrp Knockdown

  2014cites this paper
• IDENTIFICATION OF THE RNA BINDING PROTEIN RBM3 AS A NOVEL EFFECTOR OF β-CATENIN SIGNALING AND COLON CANCER STEM CELLS

  2014cites this paper
• MBL-II-141, a chromone derivative, enhances irinotecan (CPT-11) anticancer efficiency in ABCG2-positive xenografts

  2014cites this paper
• Determinants of the activity and substrate recognition of breast cancer resistance protein (ABCG2)

  2014influential citation
• Modulating Drug Resistance by Targeting BCRP/ABCG2 Using Retrovirus-Mediated RNA Interference

  2014cites this paper
• Molekularne podstawy interakcji międzylekowych w terapii nowotworów jelita grubego Molecular fundamentals of drug interactions in the therapy of colorectal cancer

  2014cites this paper
• 14. BCRP (ABCG2)

  2013cites this paper
• The effect of BCRP , MDR 1 and OATP 1 B 3 on the antitumor efficacy of the lipophilic camptothecin AR-67 in vitro

  2013influential citation
• Inhibition of ATP-Binding Cassette Transporters by Chinese Herbs and Phytochemicals

  2013cites this paper
• MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2).

  2013cites this paper
• The development and validation of a chiral high performance liquid chromatography method for the identification and quantification of (R)-enantiomer in 10-hydroxycamptothecin

  2013cites this paper
• Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment

  2013cites this paper
• ABCG2 inhibitor YHO-13351 sensitizes cancer stem/initiating-like side population cells to irinotecan.

  2013cites this paper
• PRECLINICAL AND CLINICAL DEVELOPMENT OF THE LIPOPHILIC CAMPTOTHECIN ANALOGUE AR-67

  2013cites this paper
• Analysis of Hepatic Transport Proteins

  2013cites this paper
• Acquired irinotecan resistance is accompanied by stable modifications of cell cycle dynamics independent of MSI status.

  2013cites this paper
• The Effect of Breast Cancer Resistance Protein, Multidrug Resistant Protein 1, and Organic Anion-Transporting Polypeptide 1B3 on the Antitumor Efficacy of the Lipophilic Camptothecin 7-t-Butyldimethylsilyl-10-Hydroxycamptothecin (AR-67) In Vitro

  2013cites this paper
• Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma

  2013cites this paper
• Sequence mutations of the substrate binding pocket of stem cell factor and multidrug resistance protein ABCG2 in renal cell cancer: A possible link to treatment resistance

  2013cites this paper
• Mechanisms of chemoresistance in cancer stem cells

  2013cites this paper
• ABCG2-overexpressing S1-M1-80 cell xenografts in nude mice keep original biochemistry and cell biological properties

  2012cites this paper
• Chapter 2 EZN-2208 ( PEG-SN 38 ) overcomes ABCG 2-mediated topotecan resistance in BRCA 1-deficient mouse mammary tumors

  2012cites this paper
• Suppression of BCRP expression and restoration of sensitivity to chemotherapy in multidrug-resistant HCC cell line HEPG2/ADM by RNA interference.

  2012cites this paper
• PPAR gamma, bioactive lipids, and cancer progression.

  2012cites this paper
• PPAR Medicines and Human Disease: The ABCs of It All

  2012cites this paper
• Transactivation of ABCG2 through a novel cis-element in the distal promoter by constitutive androstane receptor but not pregnane X receptor in human hepatocytes.

  2012cites this paper
• EZN-2208 (PEG-SN38) Overcomes ABCG2-Mediated Topotecan Resistance in BRCA1-Deficient Mouse Mammary Tumors

  2012cites this paper
• Human ABCG2: structure, function, and its role in multidrug resistance.

  2012cites this paper
• The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.

  2012cites this paper
• Mammalian drug efflux transporters of the ATP binding cassette (ABC) family

  2012cites this paper
• Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance.

  2012influential citation
• Targeting the multidrug ABCG2 transporter with flavonoidic inhibitors: in vitro optimization and in vivo validation.

  2011cites this paper
• Method development and validation of the simultaneous determination of a novel topoisomerase 1 inhibitor, the prodrug, and the active metabolite in human plasma using column-switching LC-MS/MS, and its application in a clinical trial.

  2011cites this paper
• Contributions of TM5, ECL3 and TM6 of human BCRP to its oligomerization activities and transport functions

  2011cites this paper
• Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cells

  2011influential citation
• New Topoisomerase I mutations are associated with resistance to camptothecin

  2011cites this paper
• In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2).

  2011cites this paper
• Topoisomerase I Inhibitors – The Camptothecins

  2011cites this paper
• The challenge of exploiting ABCG2 in the clinic.

  2011cites this paper
• Expression and functions of the repressor element 1 (RE‐1)‐silencing transcription factor (REST) in breast cancer

  2010cites this paper
• BCRP/ABCG2 confers anticancer drug resistance without covalent dimerization

  2010cites this paper
• Nanomedicinal strategies to treat multidrug-resistant tumors: current progress.

  2010cites this paper
• Inhibition of epidermal growth factor receptor-overexpressing cancer cells by camptothecin, 20-(N,N-diethyl) glycinate.

  2010cites this paper
• Drug discovery and design for complex diseases through QSAR computational methods.

  2010cites this paper
• P-glycoprotein, but not multidrug resistance protein 4, plays a role in the systemic clearance of irinotecan and SN-38 in mice.

  2010influential citation
• Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non–small-cell lung cancer

  2010cites this paper